Future studies are warranted to delineate the molecular mechanisms leading to GCN2 activation in different cell types including ECs and SMCs in response to various PAH-causing factors and the cell-specific role of GCN2 activation in pulmonary vascular remodeling and PAH development. This evidence concerns the gene EIF2AK4 and pulmonary arterial hypertension.